Research library

A

grade

Short-term neoadjuvant therapy with degarelix resulted in significant reductions in prostate size and PSA levels, which may improve the feasibility of subsequent ultrasound ablation treatments.

PSA declined by 87% (-7.6 ng/mL; 95% CI. -9.7 to -5.7; p < 0.001)

summary

B

grade

The shift to long-acting GnRH formulations resulted in a 21.5% reduction in injections and a significant decrease in drug costs, suggesting a potential benefit for patient management in prostate cancer.

Injections decreased by 21.5%, from 1,275,081 to 1,000,324.

summary

B

grade

The shift to long-acting GnRH formulations resulted in a 21.5% reduction in injections and a decrease in drug costs by 7.7 billion JPY per year, despite an increase in patient numbers.

Injections decreased by 21.5%, from 1,275,081 to 1,000,324.

summary

B

grade

This study highlights a strong association between hormonal therapies and bone-related adverse events, emphasizing the need for monitoring bone health in patients receiving these treatments.

Not reported in abstract.

summary

B

grade

Peribronchial cuffing is a rare pattern of lung metastasis in advanced prostate cancer that may lead to delays in diagnosis and treatment.

55% of patients died within a median of 5.3 months from radiographic detection.

summary

B

grade

This case highlights the potential for long-term survival in PTTM associated with prostate cancer when treated promptly, although further research is needed to confirm these findings.

Not reported in abstract.

summary

B

grade

High B7-H3 expression in hormone-sensitive prostate cancer is linked to worse overall survival, while in metastatic tumors, it may indicate better outcomes. These findings highlight the complexity of B7-H3 as a potential therapeutic target.

High B7-H3 expression in HSPCs portended adverse OS (HR, 1.30; CI, 1.15-1.46; q < 0.0001).

summary

C

grade

This study establishes a mouse model to investigate the effects of gender-affirming therapy on bone, revealing that puberty suppression leads to reduced bone mass, which can be partially restored with low-dose estradiol.

Not reported in abstract.

summary

B

grade

Clinicians should be vigilant for signs of pneumonitis in patients receiving apalutamide, as early intervention may improve outcomes.

summary

B

grade

ULM shows promise as a biomarker for testicular function, distinguishing HH from controls and tracking treatment response, but further research is needed to confirm its clinical utility.

Vessel density p < 0.001 and diameter p < 0.01 were reduced in azoospermia irrespective of treatment.

summary

B

grade

FSH levels may correlate with body composition changes in prostate cancer patients on ADT, but the clinical significance of these findings is unclear.

r=0.64, p=0.001 for FSH and appendicular lean mass index/fat body mass ratio.

summary

A

grade

Increased cerebellar activity correlated with reduced paedophilic interest after degarelix treatment, but the clinical implications remain unclear due to the study's limitations.

r=-0.740, p<0.001 for correlation between cerebellar activation and reduction in paedophilic interest after degarelix.

summary

A

grade

The modified injection technique for degarelix acetate resulted in significantly lower pain scores and milder injection-site reactions, potentially improving the patient experience.

VAS pain score at 72 h: 0.9±0.5 in modified group vs 2.3±1.0 in standard group, p<0.001.

summary

B

grade

The SChiMRA+ can help identify individuals at risk for future sexual offenses against children, but its predictive ability may be limited by the nature of self-reported data.

optimal cutoff of 4.5 on Part A for indicating heightened risk for sexually abusive acts

summary

B

grade

This case highlights a rare MITF mutation in metastatic prostate cancer, which may have implications for understanding aggressive disease but requires further investigation.

Not reported in abstract.

summary

B

grade

Enhanced telehealth for prostate cancer patients showed high feasibility and patient satisfaction, with completion rates exceeding 60% for all services offered.

Patient-level completion rates for remote BP monitoring were 91.9% (34 of 37).

summary

B

grade

This study suggests that urinary metabolomics may help identify biomarkers for early urinary toxicities in prostate cancer treatment, but findings need validation in larger cohorts.

Not reported in abstract.

summary

B

grade

This study reveals potential new risks associated with degarelix, including AEs not listed on the drug label, emphasizing the need for ongoing safety monitoring.

2,984 AEs associated with degarelix from 17,048,812 total reports in FAERS.

summary

B

grade

This case highlights the need to consider prostate cancer as a potential cause of stroke in younger patients and the importance of monitoring thrombotic markers.

Not reported in abstract.

summary